Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

Share Price is delayed by 15 minutes
Get Live Data
1,078.50    26.00 (2.47%)
Bid:
1,071.00
Ask:
1,072.00
Spread: 1.00 (0.093%)
Market Cap: £3.46b
PSN Live PriceLast checked at - London Stock Exchange

Intraday Persimmon Share Chart

Interim Management Statement

22 Apr 2010 07:00

RNS Number : 5867K
Persimmon PLC
22 April 2010
 



INTERIM MANAGEMENT STATEMENT

THURSDAY 22 APRIL 2010

 

 

 

Persimmon plc is holding its Annual General Meeting at 12 noon today at York Racecourse where the following comments will be made regarding current trading, financial performance and the outlook for the financial year. This statement, which supplements the update given at the time of our 2009 results, covers the period from 1 January 2010 to the date of this announcement and constitutes Persimmon Plc's first Interim Management Statement in 2010.

 

Since we announced our results for the year ended 31 December 2009 on 2 March 2010 weekly sales volumes have remained consistent despite a backdrop of continued uncertainty regarding the wider economic outlook and the forthcoming General Election. Total sales, including legal completions to date, are c. 20% ahead of last year at c. £1.15 billion. Sales volumes are c. 11% ahead including a higher content of private sales and prices remain firm. Encouragingly, weekly visitors per site are constant with good conversion to reservations. Cancellation rates remain at historically low levels.

 

Maintaining an appropriate level of sales while focusing on achieving price growth in all regions continues to form the basis of our current strategy. Margin improvement remains a priority.

 

We are opening new developments in line with our planned investment programme while closely monitoring working capital levels across the business. We are currently operating from c. 375 sites having opened 50 new sites through the first quarter of the year in line with our expectations. We have a further 40 sites which we currently intend to start during the second quarter. These new site openings will provide us with the opportunity to secure some further price improvement and maintain sales momentum.

 

We continue to focus on minimising build costs and on the strict control of overhead costs.

 

Against this background of trading we are carefully selecting land opportunities for investment. Whilst we continue to apply strict criteria to land purchases, we have recently acquired some excellent sites including some from our strategic land portfolio upon which we have now received residential planning consents. This new land will generate higher margins as development commences during the next 12 months.

 

At the end of March, the point in the financial year where we approach our traditional peak seasonal working capital requirements, net borrowings were at c. £265 million (31 March 2009: £680 million). Debt levels are expected to reduce further as the year progresses.

 

With margin improvement underway, cash generation remaining robust, and our high quality consented and strategic landbanks, we are in a strong position in the UK housing market to deliver profitable growth.

 

We will give a further update on trading on Tuesday 6 July 2010 following the half year end.

 

For further information, please contact:

 

 

M:Communications

Edward Orlebar

Tel: +44 (0) 7738 724 630

Charlotte McMullen

Tel: +44 (0) 207 920 2349

Marylène Guernier

Tel: +44 (0) 7776 303 788

 

Persimmon plc

Mike Farley, Group Chief Executive

Mike Killoran, Group Finance Director

Tel: +44 (0) 1904 642199

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSUAVNRROASUAR
Date   Source Headline
1st May 20257:00 amRNSAGM Trading Statement
25th Apr 202510:54 amRNSHolding(s) in Company
25th Apr 20259:24 amRNSHolding(s) in Company
11th Apr 20254:22 pmRNSHolding(s) in Company
3rd Apr 202510:15 amRNSHolding(s) in Company
2nd Apr 202512:22 pmRNSHolding(s) in Company
1st Apr 202512:03 pmRNSTotal Voting Rights
31st Mar 20253:14 pmRNSDirector/PDMR Shareholding
27th Mar 202510:08 amRNSHolding(s) in Company
25th Mar 20253:14 pmRNSDirector/PDMR Shareholding
24th Mar 20253:35 pmRNSAnnual Report 2024 and Notice of AGM 2025
24th Mar 20252:24 pmRNSHolding(s) in Company
11th Mar 20257:00 amRNSFull Year Results
6th Mar 20252:06 pmRNSHolding(s) in Company
3rd Mar 20253:35 pmRNSHolding(s) in Company
3rd Feb 202512:26 pmRNSTotal Voting Rights
14th Jan 20257:00 amRNS2024 Trading Statement
2nd Jan 20251:00 pmRNSTotal Voting Rights
10th Dec 20243:47 pmRNSDirectorate Change
2nd Dec 20242:11 pmRNSBlock listing Interim Review
2nd Dec 202412:00 pmRNSTotal Voting Rights
6th Nov 20247:00 amRNSQ3 Trading Statement
5th Nov 20241:31 pmRNSHolding(s) in Company
1st Nov 20243:59 pmRNSTotal Voting Rights
1st Oct 20241:19 pmRNSTotal Voting Rights
24th Sep 202412:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20241:44 pmRNSTotal Voting Rights
8th Aug 20247:00 amRNSHalf Year Results
1st Aug 20242:32 pmRNSTotal Voting Rights
23rd Jul 202410:28 amRNSDirectorate Change
1st Jul 20241:10 pmRNSTotal Voting Rights
19th Jun 20242:48 pmRNSDirector/PDMR Shareholding
3rd Jun 202412:33 pmRNSBlock listing Interim Review
3rd Jun 202411:08 amRNSTotal Voting Rights
23rd May 20247:00 amRNSConfirmation of CFO start date
1st May 20241:11 pmRNSTotal Voting Rights
30th Apr 20242:03 pmRNSDirectorate Change
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.